Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Invasive Nos × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 309 Polycystic Ovary Syndrome 33 Neoplasm Metastasis 19 Endometrial Neoplasms 19 Ovarian Neoplasms 14 Neoplasms 10 Advanced Breast Cancer 8 Recurrence 7 Infertility 7 Fallopian Tube Neoplasms 7 Carcinoma, Intraductal, Noninfiltrating 6 Breast Neoplasms, Male 6 Triple Negative Breast Neoplasms 5 Osteoporosis 5 Carcinoma, Lobular 5 Carcinoma, Ductal, Breast 5 Prostatic Neoplasms 4 Leiomyoma 4 Hereditary Sensory and Autonomic Neuropathies 4 Breast Diseases 4 Breast Carcinoma In Situ 4 Breast Cancer Metastatic 4 Arthralgia 4 Neoplasms, Hormone-Dependent 3 Infertility, Female 3 Carcinoma, Ovarian Epithelial 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumor 2

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡